Precision BioSciences (NASDAQ:DTIL) Posts Earnings Results, Beats Estimates By $0.20 EPS

Precision BioSciences (NASDAQ:DTIL) released its quarterly earnings data on Tuesday. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.20, Zacks reports. Precision BioSciences had a negative return on equity of 72.52% and a negative net margin of 96.73%.

Precision BioSciences Price Performance

Shares of DTIL stock traded up $0.10 during trading hours on Tuesday, hitting $7.05. The stock had a trading volume of 39,898 shares, compared to its average volume of 305,742. Precision BioSciences has a one year low of $3.53 and a one year high of $9.62. The company has a debt-to-equity ratio of 0.50, a current ratio of 12.82 and a quick ratio of 12.82. The stock’s 50-day moving average price is $6.86 and its two-hundred day moving average price is $6.52. The stock has a market capitalization of $194.61 million, a price-to-earnings ratio of -2.49 and a beta of 1.27.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Precision BioSciences in a report on Wednesday, August 5th. Wall Street Zen lowered shares of Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Finally, HC Wainwright reiterated a “buy” rating on shares of Precision BioSciences in a research report on Monday, August 3rd. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $32.25.

Precision BioSciences Company Profile

Precision BioSciences, Inc is a biotechnology company developing gene-editing medicines using its proprietary ARCUS platform. ARCUS is based on engineered DNA-cutting enzymes designed to make targeted changes to genetic material, with the potential to remove, insert or correct DNA sequences in human cells.

The company’s research and development activities have focused primarily on in vivo gene editing, in which therapeutic editing components are delivered directly into the body. Its development programs have included potential treatments for conditions such as chronic hepatitis B infection, Duchenne muscular dystrophy and certain rare genetic disorders.